[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616868":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":58,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"InventisBio Co., Ltd","INDUSTRY",[8,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: D-2570 and placebo","EXPERIMENTAL",null,[13,14],"Drug: D-2570","Drug: D-2570 Placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"Group B: D-2570 and placebo",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Group C: D-2570",[13],{"label":22,"type":23,"description":11,"interventionNames":24},"Placebo Control Group","PLACEBO_COMPARATOR",[14],[26,31],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","D-2570","Participants will be assigned to one of the following groups: Group A, Group B, Group C, or the placebo control group.",[9,16,19],{"type":27,"name":32,"description":32,"armGroupLabels":33,"otherNames":11},"D-2570 Placebo",[9,16,22],[35],{"name":36,"affiliation":37,"role":38},"Xiaofeng","Zeng","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Hang Ren, Master","CONTACT","86+15900699091","hang.ren@inventisbio.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":11,"country":51,"countryCode":52,"cosmosGeoPoint":11,"geoPoint":11,"contacts":53},"Linfen Central Hospital","RECRUITING","Linfen","Jiangxi","China","CN",[54],{"name":55,"role":42,"phone":56,"phoneExt":11,"email":57},"Shuhua Qiang","+86 18636785653","qsh18636785653@126.com",{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100616868","phase-2-a-study-of-d-2570-in-patients-with-active-systemic-lupus-erythematosus-sle-100616868",false,"NCT07311200","A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Patients With Active Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* The patient voluntarily participates in this study after full informed consent.\n* The age is 18 years ≤ age ≤ 70 years, regardless of gender.\n* Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.\n* SLEDAI-2K total score ≥ 8.\n* On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.\n\nExclusion Criteria:\n\n* History of infection as defined in the protocol.\n* Any of the medical diseases or disorders listed in the protocol.\n* Significant, uncontrolled or unstable disease in any organ.","ALL","18 Years","70 Years",{"count":71,"type":72},120,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.",[78],"Active Systemic Lupus Erythematosus",[78],"2026-04-23",{"date":82,"type":83},"2026-04-24","ACTUAL",{"date":85,"type":83},"2026-02-12",{"date":87,"type":72},"2028-12-31",{"name":5,"class":6},1]